<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245722</url>
  </required_header>
  <id_info>
    <org_study_id>FT596-101</org_study_id>
    <nct_id>NCT04245722</nct_id>
  </id_info>
  <brief_title>FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies</brief_title>
  <official_title>A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fate Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I dose-finding study of FT596 as monotherapy and in combination with
      Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic
      Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion
      stage where participants will be enrolled into indication-specific cohorts.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2020</start_date>
  <completion_date type="Anticipated">April 2037</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities within each dose level cohort</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature of dose-limiting toxicities within each dose level cohort</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature, and severity of adverse events (AEs) of FT596 as monotherapy and in combination with rituximab or obinutuzumab in r/r B-cell lymphomas and r/r chronic lymphocytic leukemia</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed objective-response rate (ORR)</measure>
    <time_frame>From baseline tumor assessment up to approximately 2 years after last dose of FT596</time_frame>
    <description>Proportion of subjects who achieve a partial response (PR) or complete response (CR) per Lugano 2014 classification for lymphomas, a partial remission (PR) or complete remission (CR) per revised iwCLL guidelines for CLL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed duration of objective response (DOR)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Defined as the duration from the first occurrence of a documented objective response (DOR) until the time of disease progression or relapse, or death from any cause, whichever occurs first, per Lugano 2014 classification for lymphomas or revised iwCLL guidelines for CLL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed duration of complete response (DoCR)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Defined as the duration from the first occurrence of a documented complete response (CR) per Lugano 2014 classification for lympohomas or complete remission (CR) per revised iwCLL guidelines for CLL, until the time of disease progression or relapse, or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Defined as the time from from first dose of lympho-conditioning to progressive disease (PD), or to the day of death for any reason, whichever occurs earlier, based on Lugano 2014 classification for lymphomas or revised iwCLL guidelinelines for CLL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS), defined as the time from first dose of lympho-conditioning to death from any cause.</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetics of FT596 in peripheral blood will be reported as the relative percentage of product (FT596) DNA versus patient DNA (% chimerism) measured from blood samples at the specified time points</measure>
    <time_frame>Study Days: 1, 2, 4, 8, 11, 15, 18, 22, 29, 43, 57</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>FT596 Monotherapy, Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT596 monotherapy in adult subjects with r/r B-cell Lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT596 in Combination with Rituximab, Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT596 in combination with Rituximab in adult subjects with r/r B-cell Lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT596 in Combination with Obinutuzumab, Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT596 in combination with Obinutuzumab in adult subjects with r/r B-cell Lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT596 Monotherapy, CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT596 monotherapy in adult subjects with r/r CLL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FT596 in Combination with Obinutuzumab, CLL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FT596 in combination with Obinutuzumab in adult subjects with r/r CLL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT596</intervention_name>
    <description>Experimental Interventional Therapy</description>
    <arm_group_label>FT596 Monotherapy, CLL</arm_group_label>
    <arm_group_label>FT596 Monotherapy, Lymphoma</arm_group_label>
    <arm_group_label>FT596 in Combination with Obinutuzumab, CLL</arm_group_label>
    <arm_group_label>FT596 in Combination with Obinutuzumab, Lymphoma</arm_group_label>
    <arm_group_label>FT596 in Combination with Rituximab, Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>FT596 Monotherapy, CLL</arm_group_label>
    <arm_group_label>FT596 Monotherapy, Lymphoma</arm_group_label>
    <arm_group_label>FT596 in Combination with Obinutuzumab, CLL</arm_group_label>
    <arm_group_label>FT596 in Combination with Obinutuzumab, Lymphoma</arm_group_label>
    <arm_group_label>FT596 in Combination with Rituximab, Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>FT596 Monotherapy, CLL</arm_group_label>
    <arm_group_label>FT596 Monotherapy, Lymphoma</arm_group_label>
    <arm_group_label>FT596 in Combination with Obinutuzumab, CLL</arm_group_label>
    <arm_group_label>FT596 in Combination with Obinutuzumab, Lymphoma</arm_group_label>
    <arm_group_label>FT596 in Combination with Rituximab, Lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Monoclonal Antibody</description>
    <arm_group_label>FT596 in Combination with Rituximab, Lymphoma</arm_group_label>
    <other_name>Rituxan</other_name>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Monoclonal Antibody</description>
    <arm_group_label>FT596 in Combination with Obinutuzumab, CLL</arm_group_label>
    <arm_group_label>FT596 in Combination with Obinutuzumab, Lymphoma</arm_group_label>
    <other_name>Gazyva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Diagnosis of B-cell lymphoma or CLL as described below:

        B-Cell Lymphoma:

          -  Histologically documented lymphomas expected to express CD19 and CD20

          -  Relapsed/refractory disease following prior systemic immunochemotherapy regimen

        Chronic Lymphocytic Leukemia (CLL):

          -  Diagnosis of CLL per iwCLL guidelines

          -  Relapsed/refractory disease following at least one prior systemic treatment regimen

        ALL SUBJECTS:

          -  Capable of giving signed informed consent

          -  Age ≥ 18 years old

          -  Stated willingness to comply with study procedures and duration

          -  Contraceptive use for women and men as defined in the protocol

        Key Exclusion Criteria:

        ALL SUBJECTS:

          -  Females who are pregnant or breastfeeding

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2

          -  Body weight &lt;50 kg

          -  Evidence of insufficient organ function

          -  Receipt therapy within 2 weeks prior to Day 1 or five half-lives, whichever is
             shorter; or any investigational therapy within 28 days prior to Day 1

          -  Currently receiving or likely to require systemic immunosuppressive therapy

          -  Prior allogeneic hematopoietic stem cell transplant (HSCT) or allogeneic CAR-T within
             6 months of Day 1, or ongoing requirement for systemic GvHD therapy

          -  Prior treatment with CD19 CAR-T therapy unless documented preservation of CD19 antigen
             is provided

          -  Receipt of an allograft organ transplant

          -  Known active central nervous system (CNS) involvement by malignancy

          -  Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or
             neurodegenerative disease

          -  Clinically significant cardiovascular disease

          -  Known HIV infection

          -  Known active Hepatitis B (HBV) or Hepatitis C (HCV) infection

          -  Live vaccine &lt;6 weeks prior to start of lympho-conditioning

          -  Known allergy to albumin (human) or DMSO
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne Chu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fate Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Payne</last_name>
    <phone>858-875-1800</phone>
    <email>clinical@fatetherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Weymer</last_name>
    <phone>858-875-1800</phone>
    <email>clinical@fatetherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell. 2018 Aug 2;23(2):181-192.e5. doi: 10.1016/j.stem.2018.06.002. Epub 2018 Jun 28.</citation>
    <PMID>30082067</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 18, 2020</study_first_submitted>
  <study_first_submitted_qc>January 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

